Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT02871843 |
| Title | Phase 1 Two Part Dose Escalation Trial of RRx-001 + Radiation + Temozolomide and RRx-001 + Temozolomide Post-RT In Newly Diagnosed Glioblastoma and Anaplastic Gliomas (G-FORCE-1) |
| Acronym | G-FORCE-1 |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | EpicentRx, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of California San Francisco (UCSF) | San Francisco | California | 94143 | United States | Details | |
| The Cancer Institute of New Jersey (Rutgers University) | New Brunswick | New Jersey | 08903 | United States | Details | |
| Weill Cornell Brain Tumor Center | New York | New York | 10021 | United States | Details |